Skip to content
MarketScale
‹ Back to IndustriesSciences

Elon Musk Successfully Launches the Falcon Heavy Rocket

Elon Musk has made it his life mission to take humankind to space. On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth. After a brief…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
Elon Musk Successfully Launches the Falcon Heavy Rocket

Key takeaways

01

Elon Musk has made it his life mission to take humankind to space.

02

On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Elon Musk has made it his life mission to take humankind to space. On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth. After a brief two-hour delay, the launch departed from Kennedy Space Center in Cape Canaveral, Florida—the same location from which NASA’s Apollo moon missions and space shuttles departed from.

The rocket itself is impressive. It stands at a massive 23 stories tall and is powered by 27 engines on three core boosters, which produces 5 million lbs. of thrust at liftoff. SpaceX, ever the innovator in composite applications, engineered the rocket’s payload fairing with a composite structure and carbon fiber face sheets that were manufactured in-house. It’s built to protect satellites during delivery to low-Earth orbit as well as geosynchronous transfer orbit.

That Tesla Roadster is something to see as well. Equipped with a mannequin named “Starman” after the 1972 David Bowie song, and a dashboard message of “Don’t Panic!” from the book Hitchhiker’s Guide to the Galaxy by Douglas Adams, the cherry red convertible is currently on a trajectory taking it past Mars, and on its way to orbit the sun. You can watch footage of it here.

After the success of the launch, two of the core boosters, designed to be reusable, returned to their designated areas in Cape Canaveral Air Force Station. The third was set to land on a landing pad in the Atlantic Ocean. It missed—taking out a drone ship nearby, and plunging into the water at 300 miles per hour. Despite this miscalculation, the test run was still a huge success for the future of space exploration and space travel.

“I think it’s going to open up a sense of possibility,” Musk was widely reported to have said after the launch. “We want a new space race. Space races are exciting.”

SpaceX is ready to lead the charge. With the success of the test run, the next steps include commercial satellite launches for the U.S. Air Force and a solar-sail mission for The Planetary Society. After that, SpaceX wants to send people to Mars as early as 2024.

“Crazy things can come true,” Musk added. “When I see a rocket lift off, I see a thousand things that could not work, and it’s amazing when they do.” Some of those amazing things working where they shouldn’t are undoubtedly because of the use of composites.

Magnum Venus Products is an innovator of composites, pumping and spraying equipment for closed/open molds, adhesives, and epoxies. MVP serves a multitude of manufacturers in a variety of industries such as automotive, aerospace, transportation, marine, railway, and oil & gas among many others. For more information on the great products MVP offers, visit the website!

Read more at mvpind.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech is investing $750 million in a new fill-finish plant in Hillsboro. The facility will focus on the production of prefilled syringes and autoinjectors. The site is expected to become operational in 2031.

  • 01Genentech is investing $750 million in a new Hillsboro facility.
  • 02The facility will produce prefilled syringes and autoinjectors.
  • 03Operations at the plant are expected to begin in 2031.

Aug 27, 2026

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio's cell-free hpDNA will be used by Genezen as starting material for viral vectors, potentially reducing the need for AAV input DNA by 30%. This innovation may lead to changes in the specification of plasmids and project timelines in gene therapy programs.

  • 01Genezen will utilize 4basebio’s cell-free hpDNA for viral vector production.
  • 02This approach could reduce AAV input DNA requirements by 30%.
  • 03The adoption of hpDNA could lead to changes in plasmid specification and project timelines.

Aug 27, 2026

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512